Conventional genetic tools, such as Tie2 or VE-cadherin (Cdh5) promoter-driven Cre recombinase, target endothelial cells almost ubiquitously in most organs of the body. 11, 12 The development of tissue-specific vascular Cre tools to enhance precision of genetic targeting would advance our understanding of endothelial cell function in organ formation and disease. Recent transcriptomic profiling as well as other technologies have provided tremendous insight into the unique profiles of angiocrine factors, adhesion molecules, chemokines, transcription factors, and metabolic regulators of endothelial cells in different tissues. 6 However, none of these genes, individually, define endothelial cells of a particular organ; rather, a combination of several genes is required to constitute a unique molecular signature. Thus, in practice, the targeting of a single endothelial cell type of an organ requires a new strategy that uses a combination of different markers to achieve the requisite specificity.
To date, genetic targeting tools have been built on the most widely used Cre-loxP homologous recombination system. 13 Thousands of Cre and floxed mouse alleles (loxP flanked genes) have been generated to address diverse questions on cell lineage and gene function. The precision of this system largely depends on the specificity of Cre expression, which is usually driven by a single gene promoter.
14 Although powerful, this conventional approach has inherent limitations, such as incomplete specificity, which has led to some discrepancies, and even controversies, in data interpretation. 15 Recently, we and others sought a more precise targeting approach, using different site-specific recombinases, under the control of multiple promoters, for genetic lineage tracing to study endogenous cell fates. [16] [17] [18] [19] [20] However, it remained unclear whether this approach could be used for genetic manipulation in vivo, for example, knockout of conventional floxed alleles. Here, we report a gene targeting system that exploits 2 recombination systems, Drerox and Cre-loxP, for their sequential intersectional genetics, whereby Dre-rox controls Cre expression such that Cre activity is restricted within, and defined by, the intersection of 2 gene expression domains. As proof-of-principle, we first validated the intersectional genetic system by generation of new mouse lines. These were then applied toward genetic targeting, achieving both gene knockout and overexpression, selectively in endothelial cells of distinct organ systems, namely the heart and brain. This valuable technology has broad applicability as a means to target organ-specific vasculatures and can also be extended to target further cellular compartments in other key organs to facilitate better understanding of gene functions.
Methods
The authors will make all data, analytic methods, and study materials available to other researchers. The authors declare that all data that support the findings of this study are available within the article and its Online Data Supplement.
Mouse Generation, Breeding, and Genotyping
All animal studies were performed in accordance with the guidelines in the Institutional Animal Care and Use Committee of the Institute for Nutritional Sciences and the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Science. Nrg1-CrexER, Nrg1-CreER, Wt1-CrexER, Tie2-Dre, Mfsd2a-CrexER mouse lines were generated by homologous recombination using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/Cas9) technology. For the Nrg1-CrexER line, CrexER was generated by insertion of 2 rox sequences flanking ER T2 : Cre-rox-ER-rox. cDNA encoding CrexER was inserted into the translational start codon ATG of the Nrg1 gene and followed by a polyadenylation sequence. What New Information Does This Article Contribute?
• Combination of Dre-rox and Cre-loxP recombination systems enhances the precision of genetic targeting.
• Sequential intersection genetics permits more precise gene manipulation in specific cell population.
• Coronary endothelial cell-specific Cre or brain endothelial cell-specific
Cre are generated and validated for gene manipulation.
• Vascular endothelial growth factor signaling regulates angiogenesis and the integrity of the blood-brain barrier.
More precise genetic targeting is important to better understand the gene function in organ development, diseases, and tissue regeneration. In this study, a sequential intersectional genetics mediated by dual recombination systems Dre-rox and Cre-loxP permits more precise gene manipulation. This dual recombinases-mediated gene targeting system could be used for generation of coronary or brain blood vessels-specific Cre tools. By these new Cre lines, gene deletion or overexpression could be achieved in coronary vessels or brain vessels efficiently and specifically. Although blood vessels are heterogenous in function among different organs, this new genetic system would help us to delineate the molecular mechanism regulating their distinct functions in organ-specific manner. June 22, 2018
cDNA, followed by a polyadenylation sequence, was inserted into the last coding exon of Nrg1 gene, and a 2A peptide sequence was used to link the Nrg1 coding region and CreER T2 cDNA to allow expression of both Nrg1 and CreER
T2
. For the Wt1-CrexER mouse line, the cDNA encoding CrexER was inserted into the translational start site of the Wt1 gene and followed by a polyadenylation sequence. For the Tie2-Dre mouse line, cDNA encoding Dre recombinase, followed by a polyadenylation sequence, was inserted into the translation start site of the Tie2 gene. For the Mfsd2a-CrexER mouse line, the cDNA encoding CrexER was inserted into the translation start site of the Mfsd2a gene. These mouse lines were generated by Shanghai Biomodel Organism Co, Ltd, China. R26-LacZ, R26-rox-LacZ, R26-tdTomato, R26-rox-tdTomato, ACTB-Cre, CAG-Dre, Kdr-flox, R26-iDTR, and Mfsd2a-CreER mice were described previously. [21] [22] [23] [24] [25] [26] [27] A list of genomic polymerase chain reaction primer for these mice was included in Online Table I . All experimental mice were maintained on 129, C57BL6 and ICR mixed backgrounds. Tamoxifen (sigma, T5648) was dissolved in corn oil and administered to mice at the indicated time. Adult animals received 0.1 mg tamoxifen per gram mouse body weight by oral gavage.
In Situ Hybridization
In situ hybridization was performed according to a protocol described previously. 18 Briefly, dissected embryos were fixed overnight in fresh 4% paraformaldehyde (PFA) and embedded in optimal cutting temperature (OCT; Sakura) after dehydration in 30% sucrose. Cryosections of 8 to 10 μm thickness were treated with hybridization buffer containing 1 μg/mL digoxigenin-labeled probes overnight at 65°C. Slides were washed for 10 minutes in MABT (maleic acid buffer containing Tween 20) buffer at room temperature, and slides were washed in SSC (saline-sodium citrate) buffer for 1 hour at 65°C. After incubating with blocking buffer (10% sheep serum and 2% blocking reagent in MABT buffer) at room temperature for 1 hour, slides were stained with anti-digoxigenin antibody (Roche, 11093274910) diluted in blocking buffer at 4°C overnight. Then the slides were washed in MABT buffer and equilibrated in alkaline phosphatase buffer, and signals were developed with NBT and BCIP (nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate, respectively; Promega, S3771) in the dark. Images were obtained on an Olympus microscope (BX53). The following primers were used to construct Nrg1 probes: forward, GACTAGTGCTGTCTGCTTTTCCTCCCTTAC, reverse, ATAAGAATGCGGCCGCCCTCATCCTCCACTATCCTCAATG.
X-Gal Staining
Embryos were dissected in cold PBS and fixed in LacZ fix solution (0.2% glutaraldehyde, 5 mmol/L EGTA [pH 7.3], and 0.1 mol/L MgCl 2 in PBS) for 30 minutes on ice with gentle shaking. After washing with LacZ wash buffer (0.01% sodium deoxycholate, 0.02% Nonidet-P40, and 2 mmol/L MgCl 2 in 100 mmol/L sodium phosphate buffer) 3× for 30 minutes, embryos were stained with LacZ staining buffer containing 1 mg/mL X-gal at 37°C overnight to the desired extent. During the staining process, embryos were protected from light. Then embryos were washed with LacZ wash buffer 3×, and whole-mount images were acquired using a Zeiss stereomicroscope (AXIO Zoom. V16).
Immunostaining
Immunostaining was performed as previously described. 28 In detail, dissected tissues were fixed in 4% PFA (Sigma) at 4°C for 20 to 60 minutes, depending on the tissue size. Afterward, tissues were washed in PBS for 3×, dehydrated in 30% sucrose overnight at 4°C, and then embedded in OCT (Sakura) for cryosectioning. Cryosections (8-10 μm) were obtained and air dried at room temperature. For staining, sections were washed in PBS for 5 minutes, incubated in blocking buffer containing 5% normal donkey serum (Jackson Immunoresearch), 0.1% Triton X-100 in PBS for 30 minutes at room temperature. Sections were then stained with the primary antibodies overnight at 4°C. Signals were developed with Alexa fluorescence antibodies (Invitrogen). Horseradish peroxidase-conjugated secondary antibodies with tyramide signal amplification kit (PerkinElmer) were used to amplify weak signals. Nuclei were counterstained with 4′6-diamidino-2-phenylindole (Vector lab). The following antibodies were used: RFP/ 
Fluorescence-Activated Cell Sorter Analysis of Brain Endothelial Cells
Brains of neonatal mice were dissected to remove pial membrane and minced into 1 to 2 mm fragments in cold PBS. Then tissues were dissociated in type IV collagenase (400U/mL, Worthington) and DNase I (32U/mL, Worthington) in PBS with Ca 2+ and Mg 2+ (Hyclone) at 37°C on a rotator for 30 minutes. After disaggregation, cells were washed in cold PBS and passed through a 40-μm filter followed by centrifugation for 5 minutes at 500g. Supernatant was discarded, and cell pellet was resuspended in 20% BSA and centrifuged at 1000g for 15 minutes to remove the myelin. The red blood cells were lysed with red blood cell lysis buffer. Afterward, the cells were washed in PBS and stained with the Violet Dye (Invitrogen, L34955) to exclude dead cells according to the manufacture's instruction. After washing in PBS, the cells were blocked with CD16/32 (eBioscience, 14-0161) and stained with CD31-APC (eBioscience, 17-0311) to label endothelial cells at 4°C for 30 minutes. The stained cells were analyzed using a fluorescenceactivated cell sorter Aria II Flow Cytometer (BD Bioscience).
Hypoxia Analysis
Hypoxia levels were assessed by Hypoxyprobe-1 Omni Kit (Hypoxyprobe Inc), according to the manufacturer's protocols. 29 Mice were injected intraperitoneally with 60 to 100 mg/kg pimonidazole HCl. One hour later, brains were collected and fixed in 4% PFA, then washed in PBS, dehydrated in 30% sucrose, and frozen in OCT. The 10-μm sections were stained with antipimonidazole. Signals were developed with 488-Alexa Fluor-conjugated donkey anti-rabbit antibody (Invitrogen). Immunostaining images were acquired with a Zeiss confocal laser scanning microscope (LSM510) or an Olympus confocal microscope (FV1200).
Examination of Integrity of the Blood-Brain Barrier
This method was performed as described previously.
30 P0 mice were anesthetized with isoflurane. The beating heart was injected via the left ventricle with 10 μL of 10-kDa dextran tetramethylrhodamine (4 mg/mL, Invitrogen, D3312). After 5 minutes of circulation, brains were collected and fixed in 4% PFA at 4°C overnight, then washed in PBS, dehydrated in 30% sucrose, and embedded in OCT (Sakura) for cryosectioning. The 10-μm sections were postfixed in 4% PFA for 15 minutes, followed by washing in PBS, incubated in blocking buffer containing 5% normal donkey serum (Jackson Immunoresearch) and 0.1% Triton X-100 in PBS for 30 minutes at room temperature. Sections were then stained with fluorescein labeled Griffonia (Bandeiraea) Simplicifolia Lectin I (GSL I or BSL I, Vector Lab, FL-1101-5, 1:500) overnight at 4°C. Immunostained tissue images were acquired using a Zeiss confocal laser scanning microscope (LSM510) or an Olympus confocal microscope (FV1200).
Cell Ablation Experiments
For specific cell ablation experiments, adult Wt1-CrexER;Tie2-Dre;R26-iDTR mice were intraperitoneally injected with diphtheria toxin (DT) dissolved in PBS at a dose of 20 ng/g bodyweight for 2 consecutive days. Control mice received intraperitoneal injection of PBS. Hearts were collected 2 days after the last DT injection.
TUNEL Assay
Apoptosis was detected using the In Situ Cell Death Detection Kit, Fluorescein (Roche, 11684795910) according to the manufacture's instruction. Briefly, sections were fixed in 4% PFA for 10 minutes at room temperature, followed by 3 washes in PBS. Afterward, sections were incubated with blocking buffer containing 5% normal donkey serum (Jackson Immunoresearch) and 0.1% Triton X-100 in PBS for 5 minutes at 4°C. Sections were then incubated with TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) reaction mixture in a humidified chamber for 1 hour at 37°C. After washing in PBS, sections were stained with antibodies referring to the procedure described in Immunostaining. Images were acquired using a Zeiss confocal laser scanning microscope (LSM510) or an Olympus confocal microscope (FV1200).
Statistical Analysis
All data were acquired from 5 independent samples and presented as mean values±SEM. All mice were randomly assigned to different experimental groups, and investigators were blinded to genotype. Sample sizes were designed with adequate power according to the literature and our previous studies. Statistical comparisons between data sets were made with analysis of normality and variance, followed by a 2-sided unpaired Student t test for comparing differences between 2 groups. ANOVA test was used for comparison between ≥3 groups. Significance was accepted when P<0.05.
Results

Design of a New Genetic Targeting System by Combining Dre-rox and Cre-loxP
To achieve more precise, organ-selective gene manipulation, we took advantage of 2 heterospecific recombination systems: Cre-loxP and Dre-rox. Dre recombinase is similar to Cre but catalyzes recombination between different sequences, named rox sites. 31 To first verify that these 2 systems achieve orthogonal homologous recombination events, we crossed constitutive Cre or Dre (ACTB-Cre or CAG-Dre) with R26-tdTomato and Rosa26-rox-tdTomato reporter lines. [22] [23] [24] By detection of tdTomato expression, we found that Cre-loxP and Dre-rox were heterospecific in homologous recombination ( Figure 1A ), in that they showed no tdTomato by either Cre-rox or Dre-loxP recombination ( Figure 1A) . Similar results were obtained using R26-LacZ and R26-rox-LacZ reporter lines. 21, 22 We then combined these 2 orthogonal recombination systems, using 2 different promoters to drive Dre and Cre for an intersectional genetics strategy ( Figure 1B) . One key consideration in the design of this system was that the ultimate effector should be a singular Cre recombinase by intersectional genetics, such that the existing extensive mouse resource of available loxP-based alleles could be used for functional studies. To achieve this, we designed a strategy that permitted sequential Dre-mediated Cre expression in targeted cells that have expressed both Dre and Cre recombinases ( Figure 1C ). We generated a switchable CreER (CrexER), by insertion of 2 rox sites to flank the ESR (ER or ESR) of the original CreER cDNA ( Figure 1C ). By default, the Cre-ER fusion protein was restricted to the cytoplasm. 32 We predicted that Dre-rox recombination would remove ER to release Cre activity on cytoplasmic-nuclear translocation. Thus, this system incorporated 2 basic elements: A-Dre and B-CrexER, in which Dre recombinase was driven by gene A and CrexER was driven by gene B. The ultimate readout of this system was Cre, and its activity was only present in cells that expressed genes A and B. Because of the sequential recombination (Dre-rox first, Figure 1C ) in the intersection of the expression domains of gene A and B (Figure 1B) , we refer to this experimental strategy as sequential intersectional genetics.
Proof-of-Principle Study for Sequential Intersectional Genetics
As proof-of-principle for this genetic strategy and use of CrexER in an animal model, we first needed to test whether Cre-rox protein is effective after rox-ER-rox recombination by Dre. We selected a gene with a clearly defined recombination pattern, which should not be germline or sporadically activated by constitutive Cre-rox recombinase. Neither Wt1 nor Mfsd2a genes, that would be used in our subsequent experiments, were initially selected for this proof-of-principle test because of previously reported sporadic expression during early embryonic development. 33 Instead, we used the neuregulin 1 (Nrg1) gene, implicated in neural development, 34 and generated a Nrg1-CrexER line, in which CrexER cDNA was knocked into the endogenous Nrg1 locus ( Figure 1D ). Immunostaining for ESR, as a surrogate for endogenous Nrg1, showed a neural crest expression pattern ( Figure 1E ), consistent with Nrg1 in situ hybridization data (Online Figure IA) and previous studies. 34, 35 In addition, Nrg1-CrexER labeled a subset of neuronal cells in the dorsal root ganglion of the neural crest after tamoxifen induction ( Figure 1F ), which was similar to the Nrg1-CreER labeling pattern (Online Figure IB and IC) . To test whether Cre could be released from CrexER and perform subsequent recombination, we crossed Nrg1-CrexER with CAG-Dre to permit Dre-mediated excision of rox-flanked ER and assessed subsequent Cre-loxP recombination ( Figure 1G) . Without tamoxifen induction, we could detect tdTomato in the neural crest in the CAG-Dre;Nrg1-CrexER;R26-tdTomato mice ( Figure 1H ), demonstrating Cre release from CrexER specifically and efficiently in vivo. There was no detectable signal in the littermate Nrg1-CrexER;R26-tdTomato control mouse without tamoxifen treatment ( Figure 1I ), indicating no leakiness of CrexER in the absence of Dre-mediated ER excision. These data validated the feasibility of our strategy for Dre-mediated Cre expression in transgenic mouse lines and confirmed the utility of this novel CrexER module for sequential intersectional genetic targeting in vivo.
Generation of Coronary Endothelial Cell-Specific Cre (CoEC-Cre)
We chose the blood vessels of heart and brain as 2 cases in point to test our new system. Application of sequential intersectional genetics to the coronary endothelium requires 2 markers that intersect only in vascular endothelial cells of the heart. The mesothelial cell marker, Wt1, was recently reported to express in developing coronary blood vessels but not in other vessels. 36 In addition to epicardial cells, Wt1-CreER labels coronary endothelial cells in the embryonic heart. 33, 37 A second marker, Tie2, is pan-endothelial cell marker and expressed in most vessels, as well as certain populations of myeloid cells. 38 With knowledge of these gene expression profiles, we aimed to test whether the intersection of Wt1 and Tie2 could direct the precise targeting of coronary vessels (Figure 2A) . We first generated a Wt1-CrexER mouse line by insertion of CrexER in frame with the translational start codon (ATG) of the Wt1 gene (Online Figure IIA) . Immunostaining for ESR showed that CrexER was restricted to the proepicardium and epicardial cells in the developing heart at E9.5 and E10.5 (Online Figure IIB and IIC) . For the second marker, Tie2, we generated a Tie2-Dre mouse allele by knocking in a Dre cassette in frame with the ATG of the endogenous Tie2 gene (Online Figure IIIA ) and characterized this mouse by crossing with a rox reporter line R26-rox-tdTomato (Online Figure IIIB) . Whole-mount images and immunostaining on tissue sections confirmed that Tie2-Dre labeled endothelial cells in multiple organs (Online Figure IIIC-IIIE) . Based on the Tie2-Dre and Wt1-CreER expression domains (Figure 2A ), we generated Tie2-Dre;Wt1-CrexER mice to determine whether Cre activity is specific to coronary vascular endothelial cells ( Figure 2B ). Whole-mount fluorescence and immunostaining of heart sections showed both specific and efficient labeling of coronary vessels ( Figure 2C and 2D) . Quantification of the percentage of tdTomato + coronary vascular endothelial cells showed labeling of 97.15%±0.61% of endothelial cells in the compact myocardium. Immunostaining for tdTomato and VE-cad C, Whole-mount fluorescent images of Tie2-Dre;Wt1-CrexER;R26-tdTomato heart from 6-wk-old mice. Insert indicates bright-field image of the same heart. D, Immunostaining for tdTomato and CDH5 on heart section shows CDH5 + tdTomato + coronary vessels. E, Immunostaining for tdTomato and CDH5 on sections from organs of 6-wk-old Tie2-Dre;Wt1-CrexER;R26-tdTomato mice. Scale bars, 1 mm in C and E; 100 µm in D. Each image is representative of 5 individual samples. DAPI indicates 4′6-diamidino-2-phenylindole; and LV, left ventricle. June 22, 2018 VD-VF). These data demonstrate that Cre-loxP recombination occurred only in the presence of both Tie2-Dre and Wt1-CrexER. Taken together, Tie2-Dre;Wt1-CrexER (hereafter named CoEC-Cre) genetically targeted blood vessels in the heart but not in other organs.
Using CoEC-Cre for Gene Manipulation in Coronary Vascular Endothelial Cells
To examine whether this new genetic system could be used for gene deletion using conventional floxed mouse alleles, we selected VEGFR2 (Kdr) as an exemplar. Kdr is universally expressed in endothelial cells of most organs, 39 but its selective targeting in coronary arteries has not previously been possible. We, therefore, crossed CoEC-Cre (Tie2-Dre;Wt1-CrexER) with the Kdr flox line 25 to test whether Kdr could be specifically deleted in the coronary vessels but not in vessels of other organs ( Figure 3A) . To allow simultaneous tracing of targeted cells, we generated + coronary endothelial cells within the compact myocardium of mutant hearts compared with controls ( Figure 3B and 3C) . However, VEGFR2 expression was unaffected in endocardial cells of trabecular myocardium ( Figure 3B ), demonstrating that the CoEC-Cre specifically targeted Wt1-expressing coronary endothelial cells, but not endocardial endothelial cells, which do not express Wt1 in the embryonic heart. Quantification of the percentage of VEGFR2 + tdTomato + vascular endothelial cells in tdTomato + vessels showed a significant reduction in the mutant compared with controls (11.82%±2.68% versus 99.68%±0.16% in mutant and control, respectively; Figure 3D ), indicating efficient deletion of Kdr in coronary vascular endothelial cells. The deletion efficiency of Kdr did not reach the same efficiency as that of cell labeling, which was likely because of a difference in Cre recombination efficiency at individual loxP alleles and also the number of recombination events required in that of Kdr flox/flox needs both alleles to be recombined while R26-tdTomato requires only one. Furthermore, we found that, in the mutant heart, VEGFR2 To test whether our Cre tool could be used to drive overexpression of genes in coronary endothelial cells, but not in other types of vessels, we selected to overexpress human DT receptor (DTR), which is not endogenously expressed in mouse. 40 We crossed CoEC-Cre with the R26-iDTR mouse, 26 in which DTR expression is controlled by Cre-loxP recombination ( Figure 3E ). DT binds with DTR and the A subunit of DT enters into the cytoplasm and catalyzes the inactivation of elongation factor to terminate protein synthesis, inducing apoptotic death of target cells. 41 We sought to express DTR specifically in coronary endothelial cells and assess whether administration of DT could ablate DTR-expressing endothelial cells. Because DTR was identified as a membrane-anchored HB-EGF (precursor), 42 we used HB-EGF antibody to detect DTR expression in mouse tissues. Immunostaining for HB-EGF and PECAM on heart sections showed expression of DTR exclusively in coronary endothelial cells ( Figure 3F ). We did not detect HB-EGF + endothelial cells in other tissues or organs (Online Figure VII) . We next treated mice with DT for 2 days and collected heart samples 2 days after the last DT treatment for analysis. Immunostaining for HB-EGF and PECAM showed severe disruption of endothelial cell morphology, suggestive of cell death ( Figure 3G ). Apoptosis was confirmed by an increased number of TUNEL + cells in the heart sections from DT-treated Tie2-Dre;Wt1-CrexER;R26-iDTR mice compared with no DT treatment ( Figure 3H and 3I). Taken together, these gene knockout and overexpression data demonstrated that our new genetic system permits gene manipulation specifically in coronary endothelial cells, without impacting other organ systems.
Generation of Brain Endothelial Cell-Specific Cre (BEC-Cre)
Unraveling the signaling pathways that control the integrity and function of brain endothelial cells has important implications for diseases of the central nervous system, such as stroke, epilepsy, and Alzheimer disease. 43 Generation of a Cre tool that specifically and efficiently targets brain endothelial cells would aid functional studies of blood-brain barrier (BBB) regulation. Previous work showed that Mfsd2a was expressed in periportal hepatocytes and also in brain endothelial cells of the central nervous system. 27, 30 To independently map Mfsd2a expression, we took advantage of the recently generated Mfsd2a-CreER line 27 and stained tissue sections with ESR, as a surrogate for endogenous Mfsd2a. Immunostaining data showed that Mfsd2a was expressed in brain endothelial cells, and also in neurons, hepatocytes, and epithelial cells of the intestinal villus (Online Figure VIIIA-VIIID) . Mfsd2a expression was further confirmed by collecting tissues from Mfsd2a-CreER;R26-tdTomato mice at 24 to 48 hours after tamoxifen treatment (Online Figure VIIIE-VIIIH) . These data convincingly demonstrated expression of Mfsd2a in brain endothelial cells but also in other cell types.
Based on Tie2-Dre and Mfsd2a-CreER targeting domains, we predicted that their intersection would target brain endothelial cells but not neurons or other cell lineages ( Figure 4A) . We, therefore, generated a Mfsd2a-CrexER mouse allele, in which cDNA encoding CrexER was inserted into the ATG of the first exon of the Mfsd2a gene (Online Figure IXA) . Immunostaining for ESR, as a surrogate for CrexER, on Mfsd2a-CrexER mouse tissue sections showed ESR expression in periportal hepatocytes, brain endothelial cells, and also a subset of neuronal cells (Online Figure IXB and IXC) . There was no leakiness in Cre activity without tamoxifen induction (Online Figure IXD and IXE) . These data confirmed the successful generation of the Mfsd2a-CrexER mouse line, which we then crossed to generate the compound Tie2-Dre;Mfsd2a-CrexER line (hereafter named BEC-Cre) for a sequential intersectional genetics study ( Figure 4B ). Compared with Mfsd2a-CreER that targeted both brain vessels and neurons, BEC-Cre targeted brain blood vessels efficiently and specifically, without labeling any neurons ( Figure 4C and 4D) . Quantification of the percentage of tdTomato + endothelial cells in the brain showed a significant increase in BECCre compared with Mfsd2a-CreER (99.56%±0.24% versus 80.44%±2.18%; Figure 4E ) while the percentage of tdTomato + neurons was negligible in BEC-Cre compared with Mfsd2a-CreER (0.13%±0.14% versus 37.25%±11.01%; + vascular endothelial cells in tdTomato + vessels in the control and mutant groups. Data are mean±SEM; *P<0.05; n=5. E, Schematic figure showing the working principle for overexpression of diphtheria toxin receptor (DTR) in coronary endothelial cells. Immunostaining for HB-EGF (heparin-binding EGF-like growth factor) and PECAM (platelet endothelial cell adhesion molecule) on heart sections of adult Tie2-Dre;Wt1-CrexER;R26-iDTR mouse treated without DT (F) and with DT (G). H and I, Immunostaining for TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) and CDH5 on heart sections of same mice. Scale bars, 100 µm. Each figure is representative of 5 individual samples. Figure 4E ). It should be noted that, in addition to the specificity, BEC-Cre targeted endothelial cells in the brain more efficiently than conventional Mfsd2a-CreER ( Figure 4E ). Flow cytometric analysis confirmed the efficient labeling of brain endothelial cells, showing 97.02%±0.31% of endothelial cells were tdTomato + labeled by BEC-Cre (Online Figure X) . We also observed that large vessels were also robustly labeled by BEC-Cre ( Figure 4F ). Large vessels do not themselves express Mfsd2a, 27,30 but they are tdTomato + by virtue of their formation from Mfsd2a + preliminary vascular plexus that was previously labeled by BEC-Cre. In addition, BEC-Cre did not target any periportal hepatocytes nor significant number of blood vessels in other organs or tissues (Online Figure XI) . Quantification of the percentage of tdTomato + endothelial cells in brain and other organs or tissues confirmed the efficiency and specificity of the BEC-Cre mouse line ( Figure 4G ).
VEGFA-VEGFR2 Signaling Is Required for Angiogenesis and Integrity of the BBB
To test whether BEC-Cre could be used for gene deletion, we again used VEGFR2 as an example because of its ubiquitous endothelial cell expression that allows us to assess the relative specificity for deletion in vessels of the brain. For specific knockout of Kdr in brain endothelial cells, we generated Figure 5A ). The mutant was lethal at an early neonatal stage as no mutants were alive by postnatal day 10 (P10), out of 11 litters (>120 mice genotyped). We, therefore, collected brain samples at late embryonic (E15.5-E18.5) and early neonatal stages (P0-P1). In the neonatal brain, we could hardly detect any VEGFR2 + blood vessels in the mutant brain compared with controls ( Figure 5B) . Quantification data showed a significant reduction of the percentage of VEGFR2 + vessels in the mutant compared with control mice (2.91%±0.82% versus 99.79%±0.12% in mutant and control, respectively; Figure 5C ), indicating efficient deletion of Kdr in brain endothelial cells. In contrast, we did not detect any loss of VEGFR2 expression in vessels in other organs or tissues of mutant mice (Online Figure  XII) , demonstrating the specificity of Kdr deletion in brain vessels. We also observed a significant reduction in vessel density in the brain of mutants compared with the controls (131.33±13.19 versus 373.32±21.25 vessels per 10× field in mutant and control, respectively; Figure 5D ) while there was no significant change in vessel density in other organs or tissues (Online Figure XII) . Mutant brain also showed an enlarged avascular zone, and hypoxyprobe staining revealed a significantly increased hypoxia in the mutant brain compared with the control (Figure 5E ), confirming the impact of reduced brain blood vessel density on tissue oxygenation. In addition to reduced angiogenesis, the morphology of vessels in mutant brain was abnormal as many mutant vessels were dilated and twisted in a cluster ( Figure 5F ), similar to glomeruloid-like vascular bodies. Taken together, we used brain vessel-specific knockout to circumvent early lethality by conventional wholebody Kdr knockout 39 and demonstrated that Kdr was required for angiogenesis in the central nervous system.
Finally, we examined whether Kdr was required for the integrity of the BBB. By injection of 10-kDa dextran tracer into the circulation, we found that dextran tracer leaked out of capillaries and was taken up by nonvascular brain parenchymal cells of the cortex ( Figure 6A ). Immunostaining for tdTomato and TER-119, an erythrocyte marker, 44 revealed the presence of TER-119 + blood cells outside the tdTomato + blood vessels ( Figure 6B ). Consistent with this, when we stained tissue sections with Glut1, a BBB marker also expressed in erythrocytes, 45 we found a significant leakage of Glut1 + blood cells into the extravascular regions of the mutant brain (Figure 6C ), further confirming that loss of Kdr impairs vascular integrity. The mutant brains also showed changes in endothelial cell protein composition, which was consistent with a loss of barrier function. In particular, plasmalemma vesicle-associated protein, an important component of endothelial fenestrations, 46 which was normally absent from BBB endothelial cells (control; Figure 6D ), was significantly induced in the mutant brain ( Figure 6D ). Canonical WNT signaling is required for proper assembly and differentiation of blood vessels in brain. 47, 48 In our Kdr mutants, we found that expression of β-catenin (CTNNB1) was significantly reduced compared with littermate controls ( Figure 6E ). Taken together, these data indicate that the VEGF signaling pathway regulates essential genes related to BBB endothelial cell integrity. 
Discussion
Conventional genetic targeting takes advantage of Cre recombinase driven by 1 specific gene promoter that is active in, but not necessarily unique to, a particular cell population. Current biological studies require more refined gene manipulation. However, it is technically challenging to define a subpopulation of cells by a single marker. In many cases, a combination of ≥2 markers is required, as commonly accepted in the immunologic studies. Our new system exploited the concept of intersectional genetics to distinguish a subpopulation of cells from other cell lineages based on the expression of 2 genes. Indeed, this approach has previously been used to increase precision of genetic lineage tracing. [18] [19] [20] Although the dual-recombinase strategy is useful for lineage tracing, it cannot be directly applied to the study of gene function as the loxP-flanked allele is only responsive to Cre but not simultaneously to Dre. For that reason, we generated this novel genetic targeting system, in which Drerox recombination first releases Cre from CreER, to then allow Cre targeting of conventional loxP alleles. This genetic strategy incorporates the idea of intersectional genetics and sequential recombination. Defining Cre activity by 2 distinct gene promoters, rather than 1, confers a substantially greater level of precision in genetic targeting than could be achieved previously with Cre controlled by a single gene promoter. It is important to note that the effector of this system remains Cre recombinase, such that all previously generated conventional loxP alleles can be usefully incorporated. Although this strategy aims principally at enhanced specificity, it is also highly efficient in gene deletion and overexpression in the experimental examples we studied. This study provided 2 examples of relevance to the cardiovascular field, but the technology reported here could be used more broadly in other fields when a more precise genetic targeting is required. On the basis that 2, but not 1, marker could specifically define a subpopulation of cells, this system can be used for functional interrogation of the subpopulation of cells in vivo, in addition to their lineage tracing.
Although this system is specific and efficient, there are limitations, caveats, and scope for future improvements. First, this system depends on 2 distinct markers to define a cell population. However, sometimes 2 markers are insufficient to precisely define a population. Some, such as immune cells or specific subtypes of neurons, are usually defined by multiple cell surface markers that typically exceed 2. One possible solution is to use additional orthogonal recombinases, such as Flpe 49 or the recently reported Nigri recombinase, 50 to generate an additional intersection that reflects ≥3 genes. However, crossing of ≥3 lines (Flpe, Dre, Cre, or more) to loxP alleles require vast resources and time, which will limit widespread application, and, moreover, is incompatible with the ethical principle of reducing animal breeding numbers. We think that, with the advent of powerful single cell sequencing, more specific markers will emerge that will distinguish subpopulations of cells more precisely with fewer markers. Second, this system does not distinguish between cells that expressed the 2 genes driving recombination results either successively or concomitantly. It is, therefore, important that recombination results are interpreted and informed by careful expression maps of the genes that drive recombinases. Third, this system needs to be modified for temporal control of gene expression. The current system, based on Dre-controlled Cre expression, is not manually inducible, as Dre is constitutively active. To impose temporal control, we could use DreER, which works under tamoxifen induction 22 and on a different strategy, such as rox-stop-rox-Cre. This would require intersectional genes to be concurrently active genes in the target cells rather than on relying on developmentally active genes, as reported here. Alternatively, establishment of an efficient Split Cre 51 approach, using genes that define specific cell populations, could also be tested for inducible Cre release. These modifications merit further investigation and refinement in future studies. Fourth, knock-in of Cre or Dre cDNA into the genomic locus at the translational start codon replaces the endogenous gene. We, therefore, recommend insertion of recombinase cDNA into the 3′ untranslated region of the gene to avoid potential haploinsufficiency phenotypes. Although genetic approaches facilitate the study of gene function, increasingly, research requires enhanced precision in both spatial and temporal control of gene expression, which, in turn, calls for improved, more innovative methodologies for gene manipulation in the future.
